National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.
By T. Jacobson, K. Maki, C. Orringer, Peter H. Jones, P. Kris-Etherton, G. Sikand, R. La Forge, S. Daniels, Don P. Wilson, P. Morris and 15 more. Journal of Clinical Lipidology, 2015
716 citations recorded by the source corpus.
An Expert Panel convened by the National Lipid Association previously developed a consensus set of recommendations for the patient-centered management of dyslipidemia in clinical medicine (part 1). These were guided by the principle that reducing elevated levels of atherogenic cholesterol (non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol) reduces the risk for atherosclerotic cardiovascular disease. This document represents a continuation of the National Lipid Association recommendations developed by a diverse panel of experts who examined the evidence base and provided recommendations regarding the following topics: (1) lifestyle therapies; (2) groups with special considerations, including children and adolescents, women, older patients, certain ethnic and racial groups, patients infected with human immunodeficiency virus, patients with rheumatoid arthritis, and patients with residual risk despite statin and lifestyle therapies; and (3) strategies to improve patient outcomes by increasing adherence and using team-based collaborative care.
Subfields: Emergency Medicine, Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/a3f91f1baf0fc30062f8d7933c782ee345a2816a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Surgery
Citations in the corpus
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. (2016, background): “Trials were excluded for the following reasons: (1) duration of less than 6 months (a timeframe during which a clinical benefit of lipid-lowering therapy would not be expected to emerge10); (2) fewer than 50 clinical events during the course of the trial (to exclude small trials with unreliable haza”